Shire partners with arGEN-X for SIMPLE route to new rare disease treatments
This article was originally published in Scrip
Executive Summary
arGEN-X, a small European biotechnology firm focused on the discovery and development of human monoclonal antibodies from its SIMPLE antibody platform, has signed a deal with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire.